Premium
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials
Author(s) -
JullianDesayes Ingrid,
Tamisier Renaud,
Zarski JeanPierre,
AronWisnewsky Judith,
LaunoisRollinat Sandrine H.,
Trocme Candice,
Levy Patrick,
JoyeuxFaure Marie,
Pepin JeanLouis
Publication year - 2016
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.12672
Subject(s) - medicine , continuous positive airway pressure , fatty liver , randomized controlled trial , steatosis , steatohepatitis , liver injury , gastroenterology , obstructive sleep apnea , disease
Background and objective Obstructive sleep apnoea ( OSA ) could be an independent risk factor for non‐alcoholic fatty liver disease ( NAFLD ) occurrence and progression. The impact of continuous positive airway pressure ( CPAP ) treatment on non‐invasive markers of NAFLD has not been studied. The aim of this study was to evaluate the effect of 6–12 weeks of effective CPAP on the F ibro M ax test (comprising components including the S teato T est, N ash T est and F ibro T est) through three randomized sham controlled studies. Methods The F ibro M ax test was performed in 103 obstructive sleep apnoea patients (apnoea + hypopnoea index > 15/h) enrolled in a randomized study comparing sham versus effective CPAP . Results At baseline, 40.4% of patients in the sham CPAP group and 45.5% in the CPAP group exhibited liver steatosis. Furthermore, 39.6% of patients in the sham CPAP group and 58.4% in the CPAP group displayed borderline or possible non‐alcoholic steatohepatitis ( NASH ). Six to twelve weeks of effective CPAP did not demonstrate any impact on reducing steatosis, NASH or liver fibrosis even after adjustment for gender, BMI , baseline apnoea + hypopnoea index and severity of liver injury. Conclusion A number of non‐invasive markers of liver damage are increased in untreated obstructive sleep apnoea patients, potentially contributing to cardiometabolic risk, but they do not improve after 6–12 weeks of effective CPAP treatment. Clinical trial registration: NCT01196845 (ADISAS), NCT00464659 (MneSAS) and NCT00669695 (StatinflaSAS) at ClinicalTrials.gov.